CIK 0001707502 · Non-accelerated filer<br>Smaller reporting company
Solid Biosciences Inc.
Sign in to watch- Ticker
- SLDB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 900943402
- Phone
- 617-337-4680
- Business address
- 500 RUTHERFORD AVENUE, 3RD FLOOR, CHARLESTOWN, MA, 02129
- Former names
- Solid Biosciences, LLC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $24,582
- in 1 filing, $25K under 10b5-1 plans
Net −$24,582. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-03-11 | Kahn Clare Director | Purchase | +1,860 | $5.34 | $10K | 2,960 |
| 2025-02-19 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Purchase · Pre-Funded Warrants (Right to Buy) | +3,722,085 | $4.03 | $15.0M | 3,722,085 |
| 2025-02-19 | PERCEPTIVE ADVISORS LLC Director | Purchase | +5,000,000 | $4.03 | $20.1M | 11,833,539 |
| 2025-02-19 | Bain Capital Life Sciences Investors, LLC 10% owner | Purchase | +1,000,000 | $4.03 | $4.0M | 5,034,582 |
| 2025-02-19 | Bain Capital Life Sciences Investors, LLC 10% owner | Purchase · Pre-Funded Warrant (right to buy) | +6,444,170 | $4.03 | $26.0M | 6,444,170 |
| 2025-02-18 | Adage Capital Management, L.P. 10% owner | Purchase | +252,545 | $7.56 | $1.9M | 4,248,084 |
| 2025-02-14 | Hanrahan Jessie Chief Regulatory Officer | Sale 10b5-1 | −3,079 | $3.96 | $12K | 19,281 |
| 2025-02-14 | Brooks Gabriel Chief Medical Officer | Sale 10b5-1 | −3,256 | $3.96 | $13K | 22,812 |
| 2025-02-14 | Tan Kevin CFO & Treasurer | Sale 10b5-1 | −3,164 | $3.96 | $13K | 32,250 |
| 2025-02-14 | Herzich Paul Chief Technology Officer | Sale 10b5-1 | −2,688 | $3.96 | $11K | 18,388 |
| 2025-02-14 | Cumbo Alexander President and CEO | Sale 10b5-1 | −11,365 | $3.96 | $45K | 60,717 |
| 2025-02-14 | Ganot Ilan Director | Sale 10b5-1 | −1,711 | $3.96 | $7K | 14,839 |
| 2025-02-14 | Howton David T Chief Operating Officer | Sale 10b5-1 | −5,561 | $3.96 | $22K | 24,789 |
| 2025-02-13 | Hanrahan Jessie Chief Regulatory Officer | Option exercise 10b5-1 | +8,125 | 22,360 | ||
| 2025-02-13 | Hanrahan Jessie Chief Regulatory Officer | Option exercise · Restricted Stock Units 10b5-1 | −8,125 | 24,375 | ||
| 2025-02-13 | Brooks Gabriel Chief Medical Officer | Option exercise 10b5-1 | +10,937 | 26,068 | ||
| 2025-02-13 | Brooks Gabriel Chief Medical Officer | Option exercise · Restricted Stock Units 10b5-1 | −10,937 | 32,813 | ||
| 2025-02-13 | Tan Kevin CFO & Treasurer | Option exercise 10b5-1 | +10,625 | 35,414 | ||
| 2025-02-13 | Tan Kevin CFO & Treasurer | Option exercise · Restricted Stock Units 10b5-1 | −10,625 | 31,875 | ||
| 2025-02-13 | Herzich Paul Chief Technology Officer | Option exercise 10b5-1 | +7,187 | 21,076 |
Page 9 of 12 · 223 trades